AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 25, 2024 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas
April 25, 2024 05:00 ET
|
PEP-Therapy
Communiqué de presse PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patientsdans la phase Ib de l’essai clinique évaluant PEP-010dans les cancers de l’ovaire et du pancréas ...
PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers
April 25, 2024 05:00 ET
|
PEP-Therapy
Press release PEP-Therapy and Institut Curie Announce First Patients Dosedin Phase Ib Clinical Trial Evaluating PEP-010in Ovarian and Pancreatic Cancers Paris (France), April 25, 2024 – PEP-Therapy,...
Oncology Collaboration and Licensing Agreements Report and Directory 2024: In-Depth Analysis of Stage of Development and Payment Structure of Deals
April 22, 2024 06:56 ET
|
Research and Markets
Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "Oncology Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering.Oncology Collaboration and Licensing...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
April 18, 2024 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
University Cancer & Blood Center and University Health Alliance open High-Risk GI Clinic to address community needs
April 10, 2024 11:48 ET
|
University, Cancer and Blood Center
University Cancer & Blood Center and University Health Alliance open High-Risk GI Clinic to address community needs.
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
April 09, 2024 12:00 ET
|
Immuneering Corporation
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Drei-Jahres-Follow-up-Daten aus Phase-1-Studie mit individualisiertem mRNA-Immuntherapie-Kandidaten zeigen eine anhaltende Immunantwort und ein verringertes Rückfallrisiko bei einigen Patienten mit reseziertem Bauchspeicheldrüsenkrebs
April 07, 2024 14:00 ET
|
BioNTech SE
Drei-Jahres-Follow-up-Daten aus einer nichtkommerziellen Phase-1-Studie mit dem individualisierten mRNA-basierten Krebsimpfstoff-Kandidaten Autogene Cevumeran (BNT122, RO7198457) bei Patientinnen und...
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
April 07, 2024 14:00 ET
|
BioNTech SE
Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell...
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024 16:05 ET
|
Immuneering Corporation
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference